Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02212678 · ClinicalTrials.gov registry record · Phase 2
Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease
A Phase 2 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02212678: Completed Phase 2 study, sponsored by University of Minnesota.
NCT02212678 is a Phase 2 study that has completed, run by University of Minnesota. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02212678, a Phase 2 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The investigators are interested in evaluating the use of oral N-acetylcysteine (NAC) as therapy for Parkinson's Disease (PD) and measuring changes in brain and blood chemistry.
Primary Outcome
GSH levels in brain of all subjects at baseline and post-NAC (n-acetylcysteine) dosing as measured by magnetic resonance spectroscopy (MRS)
Interventions
- DRUG N-acetylcysteine capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
What the finished NCT02212678 record still lists
NCT02212678 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which N-acetylcysteine capsule is the first listed.
NCT02212678 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02212678 about?
NCT02212678 is a clinical study titled "Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease". The investigators are interested in evaluating the use of oral N-acetylcysteine (NAC) as therapy for Parkinson's Disease (PD) and measuring changes in brain and blood chemistry.
What is the current status of trial NCT02212678?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2014-09. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02212678?
The interventions under investigation include: N-acetylcysteine capsule (DRUG).
Who is sponsoring clinical trial NCT02212678?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02212678's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia